BioArctic Financial Statements From 2010 to 2024
| BIOA-B Stock | SEK 189.60 4.20 2.27% |
Check BioArctic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioArctic's main balance sheet or income statement drivers, such as , as well as many indicators such as . BioArctic financial statements analysis is a perfect complement when working with BioArctic Valuation or Volatility modules.
BioArctic |
BioArctic AB Company Operating Margin Analysis
BioArctic's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current BioArctic Operating Margin | (0.03) % |
Most of BioArctic's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioArctic AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, BioArctic AB has an Operating Margin of -0.0338%. This is 99.9% lower than that of the Healthcare sector and 99.97% lower than that of the Biotechnology industry. The operating margin for all Sweden stocks is 99.39% lower than that of the firm.
BioArctic AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioArctic's current stock value. Our valuation model uses many indicators to compare BioArctic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioArctic competition to find correlations between indicators driving BioArctic's intrinsic value. More Info.BioArctic AB is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioArctic by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioArctic's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About BioArctic Financial Statements
BioArctic stakeholders use historical fundamental indicators, such as BioArctic's revenue or net income, to determine how well the company is positioned to perform in the future. Although BioArctic investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioArctic's assets and liabilities are reflected in the revenues and expenses on BioArctic's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioArctic AB. Please read more on our technical analysis and fundamental analysis pages.
BioArctic AB , a research intensive biopharmaceutical company, develops disease modifying treatments and diagnostics for neurodegenerative diseases in Sweden. BioArctic AB was founded in 1992 and is headquartered in Stockholm, Sweden. BioArctic is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in BioArctic Stock
BioArctic financial ratios help investors to determine whether BioArctic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioArctic with respect to the benefits of owning BioArctic security.